Navigation Links
Wyeth Research Head Robert R. Ruffolo, Jr., Ph.D., Announces Retirement

- Mikael Dohlsten, M.D., Ph.D., To Succeed As President, Wyeth Research -

MADISON, N.J., April 30 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) today announced that Robert R. Ruffolo, Jr., Ph.D., 58, will retire as President, Wyeth Research and Senior Vice President, Wyeth, later this year. He will be succeeded by Mikael Dohlsten, M.D., Ph.D.

Dr. Ruffolo joined Wyeth in November 2000 and has been responsible for all pharmaceutical research and development (R&D) for the Company, including discovery, drug safety and metabolism, chemical and pharmaceutical development, clinical R&D and research operations.

"Bob Ruffolo has been the driving force of our R&D progress, establishing Wyeth as one of the research leaders in the pharmaceutical industry," says Bernard Poussot, Wyeth's President and Chief Executive Officer. "His legacy will be our pipeline, recognized as one of the industry's most innovative. Bob has helped position our company for future growth through robust research and development programs in oncology, women's health, vaccines, inflammation, cardiovascular and metabolic diseases and neuroscience -- led by our multi-platform effort in Alzheimer's."

Throughout his 31-year career in the pharmaceutical industry, Dr. Ruffolo's work has been recognized with a number of prestigious awards. In March, he was recognized by the Pharmaceutical Research and Manufacturers of America (PhRMA) with the 2008 Discoverer's Award for his efforts in the discovery and development of Coreg(R) while at GlaxoSmithKline. The Wyeth Research and Development Executive Team (RADEX), formed and chaired by Dr. Ruffolo, won the 2006 Scrip Award for Management Team of the Year. In 2005, he won the George B. Koelle Award for Scientific Excellence. In 2004, he was named Chief Scientific Officer of the Year by IBC Conferences.

Dr. Dohlsten, 49, previously was Executive Vice President within Pharmaceutical Research & Development/Medicine at Boehringer Ingelheim. He was responsible for leading the company's worldwide pharmaceutical research in the U.S., Canada, Germany, Italy, Austria and Japan - with major programs in seven therapeutic areas including respiratory, inflammation/immunology, oncology, virology, cardiovascular, metabolism and CNS. In addition, he was a member of the corporate management team responsible for reviewing all worldwide development projects and licensing opportunities. Prior to joining Boehringer Ingelheim, Dr. Dohlsten spent more than 15 years in various leadership roles in pharmaceutical research including positions with AstraZeneca and Pharmacia & Upjohn.

Dr. Dohlsten earned his Ph.D. in tumor immunology and M.D. from the University of Lund in Sweden. He also studied virology and cell biology at the Weizmann Institute in Israel and has been appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund.

"We look forward to Dr. Dohlsten's leadership as we work together to continue our success at Wyeth Research," says Bernard Poussot. "His experience with industry in a broad range of therapeutic areas, and his vision going forward, match well with our scientific objectives. We know Mikael's global experience and perspective will be an inspiration to Wyeth's outstanding research teams."

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Chairman Robert Essner Announces June 27 Retirement
2. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
3. Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
4. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
5. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
6. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
7. Wyeth Announces Executive Change in Finance Organization
8. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
9. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
10. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
11. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
Post Your Comments:
(Date:11/28/2015)... South Korea (PRWEB) , ... November 28, 2015 , ... ... class of eco-friendly avian, porcine and rodent control solutions , ... as peppermint and cinnamon oil, works across all sensory modalities including visual, smell, taste ...
(Date:11/27/2015)... Kingdom , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc ... company, announced today that it has closed the sale ... business to Guerbet (GBT- NYSE Euronext) in a transaction ... encompassed four manufacturing facilities and a total of approximately ... in the St. Louis area. ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, and ... covers a wide range of applications such as, but not limited to, biotechnology, ...
(Date:11/27/2015)... India , November 27, 2015 /PRNewswire/ ... --> Growing popularity of companion diagnostics ... in cancer biomarkers market with pharmaceutical companies ... in-demand companion diagnostic tests. ... --> Complete report on global cancer ...
Breaking Biology Technology:
(Date:11/26/2015)... Research and Markets ( ) has ... - Technology and Patent Infringement Risk Analysis" report ... --> Fingerprint sensors using capacitive technology represent ... sensor vendor Idex forecasts an increase of 360% of ... and of the fingerprint sensor market between 2014 and ...
(Date:11/20/2015)... November 20, 2015 NXTD ) ... on the growing mobile commerce market and creator of ... Pereira , was recently interviewed on The RedChip ... on this weekend on Bloomberg Europe , Bloomberg ... --> NXTD ) ("NXT-ID" or the "Company"), ...
(Date:11/19/2015)...  Based on its in-depth analysis of the biometric ... the 2015 Global Frost & Sullivan Award for Product ... this award to the company that has developed the ... the market it serves. The award recognizes the extent ... customer base demands, the overall impact it has in ...
Breaking Biology News(10 mins):